{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:02:16Z","timestamp":1784872936562,"version":"3.55.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["1K01MH135745-01A1"],"award-info":[{"award-number":["1K01MH135745-01A1"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["P30-AI 060354"],"award-info":[{"award-number":["P30-AI 060354"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To (1) assess the prevalence and patterns of HIV drug resistance (HIVDR) mutations, (2) identify correlations between different HIVDR mutations within drug classes, and (3) examine the association between resistance mutations and high HIV viral load.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a secondary analysis of retrospective data collected through the Population-based HIV Impact Assessment (PHIA) surveys conducted between 2015 and 2019 in 13 African countries. We included participants aged \u226515\u2005years with available HIVDR genotyping. The primary outcomes were (1) prevalence of HIVDR mutations, categorized by drug class into non-nucleoside reverse transcriptase inhibitors (NNRTIs), Nucleoside Reverse Transcriptase Inhibitors (NRTIs), and Protease inhibitors (PIs); (2) high HIV viral load (VL), (HIV RNA \u22651000\u2005copies\/mL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The analysis included 2292 participants, with a median age range between 31 and 41\u2005years. More than one-third of participants were not receiving ART. Of all participants, 1949 (85%) had high VL. Resistance to NNRTIs and NRTIs was the most prevalent in most countries, ranging from 43% to 60%, and 37% to 53%, respectively. Resistance to PI ranges from 0.2% to 5%. Multiple drug resistance mutations across all ART classes were strongly associated with high VL. Among NNRTIs, 16\/39 mutations (e.g. K103N, Y181C) and 18\/34 NRTI mutations (e.g. M184V, K65R) showed strong associations with high VL in \u226510 countries. For PIs, Q58E and L33F emerged as key mutations strongly associated with high VL across multiple nations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Strengthening resistance surveillance, optimising ART regimens, and improving adherence are crucial to curb resistance and sustain HIV epidemic control.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf497","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T12:57:44Z","timestamp":1766581064000},"source":"Crossref","is-referenced-by-count":0,"title":["Nationwide patterns of HIV drug resistance and high viral load in Sub-Saharan African countries"],"prefix":"10.1093","volume":"81","author":[{"given":"Abubaker Ibrahim","family":"Elbur","sequence":"first","affiliation":[{"name":"Center for Global Health, Massachusetts General Hospital , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sindhuri","family":"Gandla","sequence":"additional","affiliation":[{"name":"Ragon Institute of MGH, MIT, and Harvard , Cambridge, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Nakka","sequence":"additional","affiliation":[{"name":"Ragon Institute of MGH, MIT, and Harvard , Cambridge, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruhul","family":"Khan","sequence":"additional","affiliation":[{"name":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, & Harvard Medical School , Cambridge, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musie","family":"Ghebremichael","sequence":"additional","affiliation":[{"name":"Ragon Institute of MGH, MIT, and Harvard, Cambridge, & Harvard Medical School , Cambridge, MA, USA, and MGH Biostatistics Center, Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"2026072401114470600_dkaf497-B1","author":"WHO 2025"},{"key":"2026072401114470600_dkaf497-B2","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents 2025"},{"key":"2026072401114470600_dkaf497-B3","author":"UNAIDS"},{"key":"2026072401114470600_dkaf497-B4","author":"WHO 2019"},{"key":"2026072401114470600_dkaf497-B5","author":"UNAIDS"},{"key":"2026072401114470600_dkaf497-B6","author":"WHO 2021"},{"key":"2026072401114470600_dkaf497-B7","author":"WHO"},{"key":"2026072401114470600_dkaf497-B8","author":"WHO Regional Office for Africa 2019"},{"key":"2026072401114470600_dkaf497-B9","doi-asserted-by":"publisher","first-page":"e21661","DOI":"10.1097\/MD.0000000000021661","article-title":"High levels of HIV drug resistance among adults failing second-line antiretroviral therapy in Namibia","volume":"99","author":"Jordan","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"2026072401114470600_dkaf497-B10","doi-asserted-by":"publisher","first-page":"e25611","DOI":"10.1002\/jia2.25611","article-title":"HIV-1 transmitted drug resistance surveillance: shifting trends in study design and prevalence estimates","volume":"23","author":"Rhee","year":"2020","journal-title":"J Int AIDS Soc"},{"key":"2026072401114470600_dkaf497-B11","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jgar.2022.07.019","article-title":"Evaluation of HIV-1 drug resistance among patients failing first-line antiretroviral therapy in Ethiopia","volume":"30","author":"Getaneh","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"2026072401114470600_dkaf497-B12","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1093\/jac\/dkac056","article-title":"HIV-1 drug resistance mutations among individuals with low-level viraemia while taking combination ART in Botswana","volume":"77","author":"Bareng","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026072401114470600_dkaf497-B13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12981-021-00393-5","article-title":"Acquired HIV drug resistance and virologic monitoring in a HIV hyper-endemic setting in KwaZulu-Natal province, South Africa","volume":"18","author":"Chimukangara","year":"2021","journal-title":"AIDS Res Ther"},{"key":"2026072401114470600_dkaf497-B14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12977-020-00542-0","article-title":"Increased HIV-1 pretreatment drug resistance with consistent clade homogeneity among ART-naive HIV-1-infected individuals in Ethiopia","volume":"17","author":"Kiros","year":"2020","journal-title":"Retrovirology"},{"key":"2026072401114470600_dkaf497-B15","first-page":"56","article-title":"HIV-1 drug-resistant mutations in relation to virological failure among adults in Busia County, Kenya","volume":"33","author":"Makwaga","year":"2020","journal-title":"Afr J Health Sci"},{"key":"2026072401114470600_dkaf497-B16","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1093\/infdis\/jix089","article-title":"Impact of HIV drug resistance on HIV\/AIDS-associated mortality, new infections, and antiretroviral therapy program costs in Sub-Saharan Africa","volume":"215","author":"Phillips","year":"2017","journal-title":"J Infect Dis"},{"issue":"Suppl 9","key":"2026072401114470600_dkaf497-B17","doi-asserted-by":"publisher","first-page":"S851","DOI":"10.1093\/infdis\/jix409","article-title":"Key factors influencing the emergence of human immunodeficiency virus drug resistance in low- and middle-income countries","volume":"216","author":"Wallis","year":"2017","journal-title":"J Infect Dis"},{"key":"2026072401114470600_dkaf497-B18","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1093\/jac\/dkab406","article-title":"Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in North-Western Tanzania","volume":"77","author":"Henerico","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026072401114470600_dkaf497-B19","doi-asserted-by":"publisher","first-page":"e0241071","DOI":"10.1371\/journal.pone.0241071","article-title":"HIV drug resistance profile in South Africa: findings and implications from the 2017 national HIV household survey","volume":"15","author":"Moyo","year":"2020","journal-title":"PLoS One"},{"key":"2026072401114470600_dkaf497-B20","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/jac\/dkad010","article-title":"Emerging integrase strand transfer inhibitor drug resistance mutations among children and adults on ART in Tanzania: findings from a national representative HIV drug resistance survey","volume":"78","author":"Kamori","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2026072401114470600_dkaf497-B21","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/QAI.0000000000003027","article-title":"High levels of pretreatment HIV-1 drug resistance mutations among South African women who acquired HIV during a prospective study","volume":"91","author":"Beesham","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026072401114470600_dkaf497-B22","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3390\/v17020206","article-title":"Viral suppression and HIV drug resistance among patients on second-line antiretroviral therapy in selected health facility in Ethiopia","volume":"17","author":"Zealiyas","year":"2025","journal-title":"Viruses"},{"key":"2026072401114470600_dkaf497-B23","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.3390\/v15071458","article-title":"Pre-treatment HIV drug resistance and genetic diversity in Cameroon: implications for first-line regimens","volume":"15","author":"Fokam","year":"2023","journal-title":"Viruses"},{"key":"2026072401114470600_dkaf497-B24","doi-asserted-by":"publisher","first-page":"e0276730","DOI":"10.1371\/journal.pone.0276730","article-title":"Rate of virological failure and HIV-1 drug resistance among HIV-infected adolescents in routine follow-up on health facilities in Cameroon","volume":"17","author":"Penda","year":"2022","journal-title":"PLoS One"},{"key":"2026072401114470600_dkaf497-B25","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1093\/jac\/dkab159","article-title":"HIV drug resistance among adults initiating antiretroviral therapy in Uganda","volume":"76","author":"Watera","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2026072401114470600_dkaf497-B26","author":"Population-based HIV Impact Assessment (PHIA) Project"},{"key":"2026072401114470600_dkaf497-B27","author":"Population-based HIV Impact Assessment (PHIA) Data Use Manual"},{"key":"2026072401114470600_dkaf497-B28","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S0140-6736(23)00877-2","article-title":"The risk of sexual transmission of HIV in individuals with low-level HIV viraemia: a systematic review","volume":"402","author":"Broyles","year":"2023","journal-title":"Lancet"},{"key":"2026072401114470600_dkaf497-B29","author":"WHO 2023"},{"key":"2026072401114470600_dkaf497-B30","author":"R Core Team"},{"key":"2026072401114470600_dkaf497-B31","doi-asserted-by":"publisher","first-page":"3644","DOI":"10.1038\/s41467-024-47254-z","article-title":"HIV transmission dynamics and population-wide drug resistance in rural South Africa","volume":"15","author":"Kemp","year":"2024","journal-title":"Nat Commun"},{"key":"2026072401114470600_dkaf497-B32","doi-asserted-by":"publisher","first-page":"e0300456","DOI":"10.1371\/journal.pone.0300456","article-title":"The association between HIV pretreatment drug resistance and virological outcomes in children and adults in sub-Saharan Africa: a systematic review and meta-analysis","volume":"19","author":"Takem","year":"2024","journal-title":"PLoS One"},{"key":"2026072401114470600_dkaf497-B33","doi-asserted-by":"publisher","first-page":"e2540","DOI":"10.1002\/rmv.2540","article-title":"Prevalence and factors associated with viral non-suppression in people living with HIV receiving antiretroviral therapy in sub-saharan Africa: a systematic review and meta-analysis","volume":"34","author":"Mosha","year":"2024","journal-title":"Rev Med Virol"},{"key":"2026072401114470600_dkaf497-B34","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.ijid.2022.07.037","article-title":"Risk factors for late linkage to care and delayed antiretroviral therapy initiation among adults with HIV in sub-Saharan Africa: a systematic review and meta-analyses","volume":"122","author":"Fuge","year":"2022","journal-title":"Int J Infect Dis"},{"key":"2026072401114470600_dkaf497-B35","doi-asserted-by":"publisher","first-page":"1609743","DOI":"10.3389\/fpubh.2025.1609743","article-title":"Barriers to ART adherence in sub-Saharan Africa: a scoping review toward achieving UNAIDS 95-95-95 targets","volume":"13","author":"Magura","year":"2025","journal-title":"Front Public Health"},{"key":"2026072401114470600_dkaf497-B36","doi-asserted-by":"publisher","first-page":"e0236156","DOI":"10.1371\/journal.pone.0236156","article-title":"Prevalence and characteristics of HIV drug resistance among antiretroviral treatment (ART) experienced adolescents and young adults living with HIV in Ndola, Zambia","volume":"15","author":"Miti","year":"2020","journal-title":"PLoS One"},{"key":"2026072401114470600_dkaf497-B37","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12981-017-0161-z","article-title":"High level of HIV-1 drug resistance mutations in patients with unsuppressed viral loads in rural northern South Africa","volume":"14","author":"Etta","year":"2017","journal-title":"AIDS Res Ther"},{"key":"2026072401114470600_dkaf497-B38","doi-asserted-by":"publisher","first-page":"e27460","DOI":"10.1097\/MD.0000000000027460","article-title":"Prevalence and factors associated with HIV-1 drug resistance mutations in treatment-experienced patients in Nairobi, Kenya: a cross-sectional study","volume":"100","author":"Scriven","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"2026072401114470600_dkaf497-B39","doi-asserted-by":"publisher","DOI":"10.1177\/13596535221102690","article-title":"Acquired HIV drug resistance among adults living with HIV receiving first-line antiretroviral therapy in Rwanda: a cross-sectional nationally representative survey","volume":"27","author":"Musengimana","year":"2022","journal-title":"Antivir Ther"},{"key":"2026072401114470600_dkaf497-B40","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12985-025-02740-8","article-title":"Evaluating HIV drug resistance in the Middle East and North Africa and its associated factors: a systematic review","volume":"22","author":"Khodadad","year":"2025","journal-title":"Virol J"},{"key":"2026072401114470600_dkaf497-B41","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1186\/s12879-021-06757-6","article-title":"Drivers of HIV-1 drug resistance to non-nucleoside reverse-transcriptase inhibitors (NNRTIs) in nine Southern African countries: a modelling study","volume":"21","author":"Riou","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2026072401114470600_dkaf497-B42","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.1016\/S2352-3018(16)00016-3","article-title":"The need for second-line antiretroviral therapy in adults in sub-Saharan Africa up to 2030: a mathematical modelling study","volume":"3","author":"Estill","year":"2016","journal-title":"Lancet HIV"},{"key":"2026072401114470600_dkaf497-B43","doi-asserted-by":"publisher","first-page":"e1003037","DOI":"10.1371\/journal.pmed.1003037","article-title":"Virological suppression and clinical management in response to viremia in South African HIV treatment program: a multicenter cohort study","volume":"17","author":"Hermans","year":"2020","journal-title":"PLoS Med"},{"key":"2026072401114470600_dkaf497-B44","doi-asserted-by":"publisher","first-page":"e0220337","DOI":"10.1371\/journal.pone.0220337","article-title":"The viral load monitoring cascade in a resource-limited setting: a prospective multicentre cohort study after introduction of routine viral load monitoring in rural Lesotho","volume":"14","author":"Glass","year":"2019","journal-title":"PLoS One"},{"key":"2026072401114470600_dkaf497-B45","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1007\/s10461-023-04208-8","article-title":"Antiretroviral treatment gaps and adherence among people with HIV in the U.S. medicare program","volume":"28","author":"Li","year":"2024","journal-title":"AIDS Behav"},{"key":"2026072401114470600_dkaf497-B46","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12981-020-0258-7","article-title":"Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda","volume":"17","author":"Ayitewala","year":"2020","journal-title":"AIDS Res Ther"},{"key":"2026072401114470600_dkaf497-B47","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1186\/s12889-024-20013-x","article-title":"The viral load monitoring cascade in HIV treatment programmes in sub-Saharan Africa: a systematic review","volume":"24","author":"Kippen","year":"2024","journal-title":"BMC Public Health"},{"key":"2026072401114470600_dkaf497-B48","doi-asserted-by":"publisher","first-page":"102","DOI":"10.24875\/AIDSRev.24000004","article-title":"Adherence to antiretroviral therapy among HIV-1 patients from sub-Saharan Africa: a systematic review","volume":"26","author":"Almeida","year":"2024","journal-title":"AIDS Rev"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/3\/dkaf497\/66904234\/dkaf497.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/3\/dkaf497\/66904234\/dkaf497.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:11:48Z","timestamp":1784869908000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkaf497\/8484237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf497","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,2,2]]},"article-number":"dkaf497"}}